Alto Neuroscience
ANRO · NYSE · United States
Share price · ANRO
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ANRO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026-8.1%
Nothing announced by ANRO that day or the session before.
- 11 Nov 2026+8.9%
- 9 Nov 2026+10.5%
Nothing announced by ANRO that day or the session before.
- 6 Nov 2026+15.0%
Nothing announced by ANRO that day or the session before.
- 23 Sep 2026-10.7%
Nothing announced by ANRO that day or the session before.
- 13 Aug 2026+10.7%
- 13 Jul 2026+5.9%
- 9 Jun 2026+16.0%
Nothing announced by ANRO that day or the session before.
- 13 Apr 2026+13.0%
Nothing announced by ANRO that day or the session before.
- 11 Mar 2026+10.4%
Nothing announced by ANRO that day or the session before.
Share of unusual movement by asset
For each asset, the share of ANRO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(6 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | First-in-class oral small molecule neural plasticity enhancerSmall molecule | Major Depressive DisorderBipolar Disorder | |
| Phase 2 | PDE4Small molecule | Schizophrenia Cognitive Impairment Associated with Schizophrenia | |
| Phase 2 | Histamine H3 receptor (antagonist / inverse agonist)Small molecule | Major Depressive Disorder | |
| Phase 2 | Melatonergic (MT) receptors (agonist) + serotonin receptorSmall molecule | Major Depressive Disorder | |
| Phase 2 | Dopamine D2/D3 receptors (pramipexole component) and Neurokinin-1 (NK1) receptor (aprepitant component)Combination | Parkinson's Disease | |
| Phase 2 | Dopamine D3-preferring D3/D2 receptors (agonist) + 5-HT3 receptorSmall molecule | Major Depressive Disorder |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
2027 (2)
September 2027 (1)
November 2027 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (12)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $18M | $320M | $25M-$21M operating cash flow | report ↗ |
View 11 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $22M | $244M | $28M-$20M operating cash flow | report ↗ |
| 2026-Q1 | — | $20M | $264M | $26M-$27M operating cash flow | report ↗ |
| 2025-Q3 | — | $11M | $138M | $14M-$9.9M operating cash flow | report ↗ |
| 2025-Q2 | — | $13M | $148M | $18M-$14M operating cash flow | report ↗ |
| 2025-Q1 | — | $10.0M | $161M | $15M-$17M operating cash flow | report ↗ |
| 2024-Q3 | — | $13M | $182M | $17M-$12M operating cash flow | report ↗ |
| 2024-Q2 | — | $13M | $194M | $16M-$12M operating cash flow | report ↗ |
| 2024-Q1 | — | $9.9M | $206M | $13M-$11M operating cash flow | report ↗ |
| 2023-Q3 | — | $8.0M | $51M | $9.1M-$7.8M operating cash flow | report ↗ |
| 2023-Q2 | — | $7.1M | $59M | $8.7M-$6.6M operating cash flow | report ↗ |
| 2023-Q1 | — | $5.6M | $66M | $7.3M-$7.5M operating cash flow | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $46M | $177M | $16M-$52M operating cash flow | report ↗ |
Alto Neuroscience reported no revenue disclosed for full-year 2025. R&D spend was $45.62M, down 2.9% YoY, and cash and equivalents totaled $176.98M at year-end versus approximately $169M in the prior year. The company reported a net loss of $63.24M, with a corresponding quarterly net burn of $63.24M.
Management expects the year-end cash balance to fund operations into 2028, covering four key pipeline data readouts. Alto acquired ALTO-207 for treatment-resistant depression, with a Phase 2b trial planned for the first half of 2026 and a Phase 3 trial by early 2027; an external PAX-D study published in The Lancet Psychiatry reported a 0.87 effect size for pramipexole. ALTO-101 received FDA Fast Track Designation for cognitive impairment associated with schizophrenia, with Phase 2 proof-of-concept topline data expected around the end of the first quarter of 2026. ALTO-300 Phase 2b major depressive disorder data are expected mid-2026, and ALTO-100 Phase 2b bipolar depression data in the second half of 2026.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 8 sales ($5.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-18 | Hanley Jr. Michael Conick · CHIEF OPERATING OFFICER | Option exercise | 2,896 | $2.35 | $7K | Form 4 |
| 2026-11-18 | Hanley Jr. Michael Conick · CHIEF OPERATING OFFICER | Open-market sale | 2,896 | $26.48 | $77K | Form 4 |
| 2026-11-18 | Hanley Jr. Michael Conick · CHIEF OPERATING OFFICER | Option exercise (derivative) | 2,896 | — | — | Form 4 |
| 2026-11-17 | Hanley Jr. Michael Conick · CHIEF OPERATING OFFICER | Option exercise | 2,104 | $2.35 | $5K | Form 4 |
| 2026-11-17 | Hanley Jr. Michael Conick · CHIEF OPERATING OFFICER | Open-market sale | 2,104 | $26.82 | $56K | Form 4 |
| 2026-11-17 | Hanley Jr. Michael Conick · CHIEF OPERATING OFFICER | Option exercise (derivative) | 2,104 | — | — | Form 4 |
| 2026-11-16 | Hanley Jr. Michael Conick · CHIEF OPERATING OFFICER | Option exercise | 17,729 | $2.35 | $42K | Form 4 |
| 2026-11-16 | Hanley Jr. Michael Conick · CHIEF OPERATING OFFICER | Option exercise | 44,271 | $2.35 | $104K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 109 reporting institutions held 26.8M shares ($592.8M, 66.9% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Alpha Wave Global, LP | 3,707,757 | $83.4M |
| 2 | Commodore Capital LP | 2,723,196 | $61.2M |
| 3 | Vestal Point Capital, LP | 2,064,075 | $46.4M |
| 4 | PERCEPTIVE ADVISORS LLC | 2,009,893 | $45.2M |
| 5 | Spruce Street Capital LP | 1,325,210 | $29.1M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 1,207,025 | $27.1M |
| 7 | FRANKLIN RESOURCES INC | 1,101,874 | $24.8M |
| 8 | Vivo Capital, LLC | 1,035,551 | $23.3M |
| 9 | ARMISTICE CAPITAL, LLC | 912,000 | $20.5M |
| 10 | MILLENNIUM MANAGEMENT LLC | 821,982 | $18.5M |
| 11 | 72 Investment Holdings, LLC | 667,778 | $15.0M |
| 12 | BlackRock, Inc. | 666,188 | $15.0M |
| 13 | Ikarian Capital, LLC | 515,000 | $11.6M |
| 14 | Point72 Asset Management, L.P. | 503,087 | $11.3M |
| 15 | Venrock Adviser, LLC | 500,000 | $11.2M |